STOCK TITAN

Notable Labs - NTBL STOCK NEWS

Welcome to our dedicated page for Notable Labs news (Ticker: NTBL), a resource for investors and traders seeking the latest updates and insights on Notable Labs stock.

Notable Labs (NTBL) delivers precision oncology innovations through its Predictive Precision Medicines Platform (PPMP), advancing targeted cancer therapies and diagnostic solutions. This news hub provides investors and industry professionals with essential updates on clinical developments, strategic partnerships, and regulatory progress.

Access real-time announcements about Phase 2 trial results, biomarker discoveries, and therapeutic licensing agreements. Our curated collection includes earnings reports, research collaborations, and platform validation studies - all critical for evaluating NTBL's position in clinical-stage biotechnology.

Key updates cover ex vivo testing advancements, patient stratification methodologies, and companion diagnostic developments. Bookmark this page for streamlined tracking of NTBL's progress in transforming cancer treatment through predictive medicine and optimized dosing strategies.

Rhea-AI Summary

Notable Labs (Nasdaq: NTBL) will present data on its volasertib program for acute myeloid leukemia (AML) at the Society of Hematologic Oncology (SOHO) 2024 meeting on September 4th. The presentation will provide an overview of the upcoming Phase 2 program and additional preclinical study results.

The poster, titled 'Revival of the polo-like kinase 1 (PLK1) inhibitor volasertib in relapsed/refractory acute myeloid leukemia', will be presented during the poster session on Wednesday, September 4th at 6:15 PM CDT. Notable Labs, a clinical-stage precision oncology company, is developing new cancer therapies identified by its Predictive Medicine Platform (PMP).

The company expects to begin its Phase 2 volasertib AML program in the coming months, marking a significant step in the development of this potential treatment for AML patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.06%
Tags
conferences
-
News
Rhea-AI Summary

Notable Labs (Nasdaq: NTBL) announced a significant leadership change as CEO Thomas A. Bock, MD, resigned from his position and the Board of Directors. Joseph Wagner, PhD, the company's Chief Scientific Officer, has been appointed as interim CEO. The Board has initiated a search for Dr. Bock's successor.

Under Dr. Bock's leadership, Notable Labs transformed from a private diagnostic start-up to a publicly-traded clinical-stage company focused on Predictive Medicine. The company remains committed to its plans, including the initiation of the Phase 2 clinical program for volasertib in the coming months. Dr. Bock will continue as a consultant, advising the Board and offering expertise on the company's next phase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
Rhea-AI Summary

Notable Labs (NASDAQ: NTBL) has received FDA clearance to proceed with its Phase 2 study of volasertib for relapsed/refractory acute myeloid leukemia (R/R AML). The company plans to initiate patient enrollment in the coming months, following agreement on the dosing plan. The study will evaluate volasertib in combination with decitabine, utilizing Notable's Predictive Medicine Platform (PMP) to enhance patient outcomes.

The Phase 2 trial will begin with a dose optimization lead-in, incorporating body-surface area dosing and prophylactic antibiotic treatment. Notable expects initial data from this phase in Q4 2024, followed by selective enrollment of PMP-predicted responders. Initial efficacy results are anticipated in H1 2025. This progress marks a significant step in addressing the unmet need for R/R AML patients, particularly those who have received venetoclax-based therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
Rhea-AI Summary

Notable Labs, a clinical-stage precision oncology company, will participate in a fireside chat at the Citizens JMP Securities Life Sciences Conference 2024. The CEO, Thomas Bock, will discuss the company's cancer therapies developed using the Predictive Medicine Platform. The event will take place on May 13-14, 2024, in New York City, with a webcast accessible on the Notable Labs website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.54%
Tags
conferences
-
Rhea-AI Summary
Notable Labs, (NTBL) reported financial results for 2023, highlighted by successful clinical data from their Precision Medicine Platform. The company plans to advance its clinical program for lead product candidate, volasertib, in 2024. Notable Labs aims to leverage its platform to predict patient responses, enhance enrollment, and increase the likelihood of success. Financially, the company ended 2023 with $11.8 million in cash, with a current balance of $8.2 million as of April 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
-
Rhea-AI Summary
Notable Labs, presents the design for a Phase 2 trial with volasertib and decitabine in patients with relapsed/refractory AML at AACR 2024. The company aims to predict responders using their PPMP and develop a companion diagnostic test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.48%
Tags
Rhea-AI Summary
Notable Labs, (NTBL) presented data on innovations in using cryopreserved samples in their Precision Oncology Platform at AACR 2024. The study showed cryopreserved samples can predict treatment response in acute myeloid leukemia with high accuracy, opening new avenues for treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.15%
Tags
none
-
Rhea-AI Summary
Notable Labs, Ltd. (NTBL) announced the presentation of two posters at AACR 2024 related to their Predictive Precision Medicine Platform (PPMP) for cancer therapies. They plan to initiate a Phase 2 program for volasertib in Q2 2024. The posters focus on clinical response prediction and ex vivo tests for acute myeloid leukemia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
conferences
-
Rhea-AI Summary
Notable Labs, Ltd. (Nasdaq: NTBL) announces the advancement of its volasertib Phase 2 program utilizing Predictive Precision Medicine Platform (PPMP) to enrich the study population for clinical responders in relapsed/refractory acute myelogenous leukemia (r/r AML). PPMP's accurate predictions allow for the elimination of non-responders, reducing risk, time, and cost of drug development. Clinical milestones include IND filing in Q1 2024, program initiation in Q2 2024, dose optimization data in Q4 2024, and enrollment of the first PPMP-selected patient in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
Rhea-AI Summary
Notable Labs, Ltd. (Nasdaq: NTBL) and CicloMed, LLC announced initial safety and efficacy data of fosciclopirox and the performance of PPMP from the Phase 2a trial in adult patients with relapsed/refractory acute myeloid leukemia. Fosciclopirox, a patented prodrug, is being developed for the treatment of bladder cancer and AML. PPMP accurately predicted patient responses, further validating its potential in drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.55%
Tags
none
Notable Labs

Nasdaq:NTBL

NTBL Rankings

NTBL Stock Data

2.39M
6.27M
32.95%
4.55%
5.2%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY